A Study About Low Blood Pressure in Patients With Primary Immunodeficiency Disease Treated With Immune Globulin Products
Public ClinicalTrials.gov record NCT03037359. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Non-interventional, Observational, Prospective Study to Assess Hypotension in Patients With Primary Immunodeficiency Disease Treated With Bivigam™ (Human 10%) or Other Commercial Human 10% Immune Globulin (Intravenous) (IGIV) Products During Infusion and up to 72 Hours Post Infusion
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a safety study to evaluate the risk of low blood pressure in subjects with Primary Immune Deficiency disorder (PID) treated with Bivigam™ or another commercial product under real world conditions. No study medication will be provided to subjects in this study. Study physicians will make all treatment decisions according to their usual practice and will provide prescriptions for his/her subjects, as appropriate. The only addition is the collection and structured documentation of data generated through usual practice.
Study identification
- NCT ID
- NCT03037359
- Recruitment status
- Not listed
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- 200 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- Not listed
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 2016 (Actual)
- Primary completion
- Dec 31, 2022 (Actual)
- Completion
- Jun 30, 2023 (Estimated)
- Last update posted
- Feb 1, 2023
2016 – 2023
United States locations
- U.S. sites
- 17
- U.S. states
- 11
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Santa Barbara Specialty Pharmacy | Carpinteria | California | 93013 | — |
| Allergy and Asthma of the Bay Area | Walnut Creek | California | 94598 | — |
| Immunoe Research Centers | Centennial | Colorado | 80112 | — |
| Central Georgia Infectious Disease Consultants | Macon | Georgia | 31201 | — |
| Midwest Allergy and Sinus | Normal | Illinois | 61761 | — |
| Kanarek Adult & Pediatric Allergy & Immunology | Overland Park | Kansas | 66211 | — |
| Infectious Disease Consultants | Wichita | Kansas | 67211 | — |
| The Center for Allergy, Asthma & Immunology | Syosset | New York | 11234 | — |
| Allergy Asthma & Immunology Relief | Charlotte | North Carolina | 28204 | — |
| Ohio Clinical Research Associates | Mayfield Heights | Ohio | 44124 | — |
| Oklahoma Institute of Allergy and Asthma Clinical Research | Oklahoma City | Oklahoma | 73131 | — |
| Austin Infectious Disease Consultants | Austin | Texas | 78705 | — |
| Discovery Clinical Trials | Dallas | Texas | 75225 | — |
| Allergy Partners of North Texas | Dallas | Texas | 75230 | — |
| Allergy Immunology and Respiratory Care | Dallas | Texas | 75231 | — |
| University of Texas Southwestern Medical Center | Irving | Texas | 75390 | — |
| Lysosomal Rare Disorders Research & Treatment Center | Fairfax | Virginia | 22030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03037359, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 1, 2023 · Synced Oct 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03037359 live on ClinicalTrials.gov.